• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ReShape Lifesciences Inc. (Amendment)

    2/14/22 6:15:29 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care
    Get the next $RSLS alert in real time by email
    SC 13G/A 1 d240263dsc13ga.htm SC 13G/A SC 13G/A
    OMB APPROVAL

    OMB Number:                                          3235-0145

    Expires:                                         February 28, 2010

    Estimated average burden hours per response    10.4

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (AMENDMENT NO.         7            )*

     

     

    Reshape LifeSciences, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    76090R101

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Cusip No.

       76090R101    13G      Page 2 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Partners X, LP (“IWP X”)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      6,250

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      6,250

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0% (2)

    12  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.


    Cusip No.

       76090R101    13G      Page 3 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      InterWest Management Partners X, LLC (the General Partner of InterWest Partners X, LP)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      6,250

       6  

      SHARED VOTING POWER

     

      0

       7  

      SOLE DISPOSITIVE POWER

     

      6,250

       8  

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

    (2)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.


    Cusip No.

       76090R101    13G      Page 4 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Keval Desai (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Keval Desai that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.


    Cusip No.

       76090R101    13G      Page 5 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Gilbert H. Kliman (a Managing Director of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Gilbert H. Kliman that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.


    Cusip No.

       76090R101    13G      Page 6 of 9 Pages  

     

      1    

      NAME OF REPORTING PERSONS

     

      Khaled A. Nasr (a Venture Member of InterWest Management Partners X, LLC)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,250

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,250

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,250

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      0%

    12  

      TYPE OF REPORTING PERSON

     

      IN

    Neither the filing of this statement on Schedule 13G nor any of its contents shall be deemed to constitute an admission by Khaled A. Nasr that he is the beneficial owner of any of the Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

     


    Cusip No.

       76090R101    13G    Page 7 of 9 Pages

     

    ITEM 1.

     

    (a)

    NAME OF ISSUER : Reshape LifeSciences, Inc.

     

    (b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:

    1001 Calle Amanecer, San Clemente, CA 92673

     

    ITEM 2.

     

    (a)

    NAME OF PERSON(S) FILING:

    InterWest Partners X, LP (“IWP X”)

    InterWest Management Partners X, LLC (“IMP X”)

    Keval Desai (“Desai”)

    Gilbert H. Kliman (“Kliman”)

    Khaled A. Nasr (“Nasr”)

     

    (b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

    467 First Street, Suite 201, Los Altos, CA 94022

     

    (c)

    CITIZENSHIP/PLACE OF ORGANIZATION:

    IWP X:             California

    IMP X:             California

    Desai:               United States

    Kliman:            United States

    Nasr:                United States

     

    (d)

    TITLE OF CLASS OF SECURITIES: Common Stock

     

    (e)

    CUSIP NUMBER: 76090R101

    ITEM 3. NOT APPLICABLE.

     


    Cusip No.

       76090R101    13G    Page 8 of 9 Pages

     

    ITEM 4.

    OWNERSHIP.

     

          IWP X     IMP X (1)     Desai (2)  

    Beneficial Ownership

         6,250  (3)      6,250  (3)      6,250  (3) 

    Percentage of Class

         0 % (4)      0 % (4)      0 % (4) 

    Sole Voting Power

         6,250       6,250       0  

    Shared Voting Power

         0       0       6,250  

    Sole Dispositive Power

         6,250       6,250       0  

    Shared Dispositive Power

         0       0       6,250  

     

          Kliman (2)     Nasr (2)  

    Beneficial Ownership

         6,250  (3)      6,250  (3) 

    Percentage of Class

         0 % (4)      0 % (4) 

    Sole Voting Power

         0       0  

    Shared Voting Power

         6,250       6,250  

    Sole Dispositive Power

         0       0  

    Shared Dispositive Power

         6,250       6,250  

     

      (1)

    IMP X is the general partner of IWP X.

      (2)

    Kliman is a Managing Director of IMP X. Desai and Nasr are Venture Members of IMP X. The Managing Directors and Venture Members of IMP X share voting and investment control over shares held by IWP X.

      (3)

    The shares are owned by IWP X and include 6,250 shares of Common Stock issuable pursuant to common stock purchase warrants.

      (4)

    Based upon 17,784,027 shares of the Issuer’s Common Stock outstanding as of November 10, 2021, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021.

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited liability company operating agreement of IMP X, the members of such limited liability company have the right to receive dividends from, or the proceeds from the sale of, the common stock of Issuer beneficially owned by such limited liability company.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    No reporting person is a member of a group as defined in section 240.13d-1(b)(1)(iii)(H) of the Act.

    ITEM 9. NOTICE OF DISSOLUTION OF THE GROUP.

    Not applicable.

     


    Cusip No.

       76090R101    13G    Page 9 of 9 Pages

     

    ITEM 10.

    CERTIFICATION.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    EXHIBITS

    Joint Filing Statement attached as Exhibit A.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022
    INTERWEST PARTNERS X, LP
    By:   InterWest Management Partners X, LLC, its General Partner
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    INTERWEST MANAGEMENT PARTNERS X, LLC
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
      Managing Director
    By:   /s/ Keval Desai by Karen A. Wilson, Power of Attorney
    Name:   Keval Desai
    By:   /s/Gilbert H. Kliman by Karen A. Wilson, Power of Attorney
    Name:   Gilbert H. Kliman
    By:   /s/ Khaled A. Nasr
    Name:   Khaled A. Nasr
    Get the next $RSLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RSLS

    DatePrice TargetRatingAnalyst
    10/8/2021$8.00Buy
    Maxim Group
    More analyst ratings

    $RSLS
    SEC Filings

    View All

    ReShape Lifesciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Vyome Holdings, Inc (0001427570) (Filer)

    8/20/25 5:23:32 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by ReShape Lifesciences Inc.

    424B5 - Vyome Holdings, Inc (0001427570) (Filer)

    8/20/25 5:21:13 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Vyome Holdings, Inc (0001427570) (Filer)

    8/19/25 5:29:47 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

    Vyome Therapeutics, Inc. ("Vyome"), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (NASDAQ:RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol "HIND." About Vyome Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory cond

    8/14/25 7:18:00 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

    Effective as of Commencement of Trading on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (NASDAQ:RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol "HIND." "Nasdaq's approval is right on track and now we are marching forward to ring the bell on our planned listing date this

    8/13/25 11:50:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Stankovich Thomas sold $39 worth of shares (172 units at $0.23), decreasing direct ownership by 0.75% to 22,777 units (SEC Form 4)

    4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    8/13/24 4:29:13 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    New insider Schneid Yair claimed ownership of 2,461,000 shares (SEC Form 3)

    3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    1/16/24 6:11:06 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Stankovich Thomas sold $386 worth of shares (435 units at $0.89), decreasing direct ownership by 2% to 22,949 units (SEC Form 4)

    4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

    11/8/23 4:16:25 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Reshape Lifesciences with a new price target

    Maxim Group initiated coverage of Reshape Lifesciences with a rating of Buy and set a new price target of $8.00

    10/8/21 9:13:24 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ReShape Lifesciences Inc.

    SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)

    9/26/24 4:45:20 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by ReShape Lifesciences Inc.

    SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

    3/17/23 5:01:18 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by ReShape Lifesciences Inc.

    SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

    2/15/23 3:34:19 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Financials

    Live finance-specific insights

    View All

    ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

    IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market. Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the

    11/12/24 4:05:00 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

    IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta

    8/13/24 8:31:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

    Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma

    5/15/24 4:05:00 PM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    $RSLS
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

    IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medical Device Directive (MDD) in May 2021, sets significantly more stringent requirements for clinical evaluation, post-market surveillance, and device traceability. Its goal is to improve patient sa

    6/3/25 8:31:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

    SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer. "Nick is a proven executive

    8/23/22 8:30:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care